Omnicell, Inc. provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides automated dispensing cabinets for medications and supplies used in nursing units, operating rooms, and emergency departments; analytics software to monitor drug diversion and address inventory management issues; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. The Medication Adherence segment provides medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. It also offers Omnicell Patient Engagement, a subscription-based software system; patient communication tools, such as interactive voice response for pharmacies; and electronic Medication Administration Record software for use in nursing homes. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
Phone650-251-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$787.31 million
Profitability
Miscellaneous
Employees2,480
Next Earnings Date4/25/2019 (Estimated)
OptionableOptionable
Omnicell (NASDAQ:OMCL) Frequently Asked Questions
What is Omnicell's stock symbol?
Omnicell trades on the NASDAQ under the ticker symbol "OMCL."
How were Omnicell's earnings last quarter?
Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings data on Thursday, February, 7th. The company reported $0.70 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.54 by $0.16. The business had revenue of $211.75 million for the quarter, compared to the consensus estimate of $215.41 million. Omnicell had a return on equity of 9.31% and a net margin of 4.79%. The business's revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.55 earnings per share. View Omnicell's Earnings History.
When is Omnicell's next earnings date?
What guidance has Omnicell issued on next quarter's earnings?
Omnicell issued an update on its FY19 earnings guidance on Thursday, February, 7th. The company provided earnings per share guidance of $2.40 to $2.60 for the period, compared to the Thomson Reuters consensus estimate of $2.41. Omnicell also updated its Q1 guidance to $0.38 to $0.43 EPS.
What price target have analysts set for OMCL?
7 Wall Street analysts have issued twelve-month target prices for Omnicell's stock. Their predictions range from $61.00 to $90.00. On average, they expect Omnicell's stock price to reach $78.00 in the next year. This suggests that the stock has a possible downside of 5.8%. View Analyst Price Targets for Omnicell.
What is the consensus analysts' recommendation for Omnicell?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omnicell.
Has Omnicell been receiving favorable news coverage?
Media headlines about OMCL stock have trended very negative on Thursday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Omnicell earned a coverage optimism score of -3.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of Omnicell's key competitors?
What other stocks do shareholders of Omnicell own?
Who are Omnicell's key executives?
Omnicell's management team includes the folowing people:
- Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 62)
- Mr. Peter J. Kuipers, Exec. VP & CFO (Age 47)
- Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 55)
- Mr. Robin G. Seim, Pres of Global Automation & Medication Adherence (Age 59)
- Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 59)
Who are Omnicell's major shareholders?
Omnicell's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.91%), Conestoga Capital Advisors LLC (3.86%), Dimensional Fund Advisors LP (3.41%), Eagle Asset Management Inc. (2.38%), Bank of New York Mellon Corp (2.36%) and Northern Trust Corp (1.36%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Robin Gene Seim. View Institutional Ownership Trends for Omnicell.
Which institutional investors are selling Omnicell stock?
OMCL stock was sold by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, WINTON GROUP Ltd, Thrivent Financial for Lutherans, Elk Creek Partners LLC, Dimensional Fund Advisors LP, Falcon Point Capital LLC, Copper Rock Capital Partners LLC and Kornitzer Capital Management Inc. KS. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, James T Judson, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Robin Gene Seim. View Insider Buying and Selling for Omnicell.
Which institutional investors are buying Omnicell stock?
OMCL stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Stifel Financial Corp, Amundi Pioneer Asset Management Inc., Millennium Management LLC, Lisanti Capital Growth LLC, Geode Capital Management LLC, Geode Capital Management LLC and Tygh Capital Management Inc.. View Insider Buying and Selling for Omnicell.
How do I buy shares of Omnicell?
Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Omnicell's stock price today?
One share of OMCL stock can currently be purchased for approximately $82.78.
How big of a company is Omnicell?
Omnicell has a market capitalization of $3.38 billion and generates $787.31 million in revenue each year. The company earns $37.73 million in net income (profit) each year or $1.53 on an earnings per share basis. Omnicell employs 2,480 workers across the globe.
What is Omnicell's official website?
How can I contact Omnicell?
Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]
MarketBeat Community Rating for Omnicell (NASDAQ OMCL)
MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe OMCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.
